22 May 2013
Keywords: spectrum, sees, strong, results, bladder, cancer, study
Article | 28 April 2005
US oncology firm Spectrum Pharmaceuticals says that its proprietary anticancer drug Intravesical EOquin has achieved a 66% complete response
rate in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 December 2004
21 May 2013
© 2013 thepharmaletter.com